Scynexis Inc is a biotechnology company focused on developing innovative therapies to combat serious infections, particularly those caused by resistant pathogens. The company specializes in researching and advancing novel antifungal treatments aimed at addressing unmet medical needs in infectious diseases. By leveraging its proprietary drug development platform, Scynexis seeks to create transformative solutions that enhance patient outcomes and improve the management of challenging infections in both hospital and outpatient settings. Through its commitment to scientific excellence and rigorous clinical testing, Scynexis strives to make a meaningful impact on public health by providing effective alternatives for patients facing difficult-to-treat infections.
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite trading higher by around 30 points on Monday. The Dow traded down 0.07% to 33,939.93 while the NASDAQ rose 0.24% to 13,243.56. The S&P 500 also rose, gaining, 0.19% to 4,328.30.
Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares jumped 308% to $2.71 after the company announced pre-clinical gliblastoma results with its lead candidate, TTX-MC138.
U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite trading higher on Monday. The Dow traded down 0.01% to 33,962.53 while the NASDAQ rose 0.26% to 13,246.15. The S&P 500 also rose, gaining, 0.22% to 4,329.75.
U.S. stocks traded mostly lower this morning, with the Dow Jones trading falling around 80 points on Monday. Following the market opening Monday, the Dow traded down 0.26% to 33,875.83 while the NASDAQ fell 0.05% to 13,205.29. The S&P 500 also fell, dropping, 0.13% to 4,314.62.
